Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14855867 | 1.00 | BACE1 (0.63) | BACE1KCNH2BACE2APP | |
| SCHEMBL362425 | 1.00 | BACE1 (0.63) | BACE1KCNH2BACE2APP | |
| SCHEMBL11993563 | 0.91 | BACE1 (0.53) | BACE1KCNH2BACE2APP | |
| Trifluoroacetic Acid SCHEMBL14889615 | 0.88 | BACE1 (0.59) | BACE1KCNH2APP | |
| SCHEMBL370974 | 0.85 | BACE1 (0.66) | BACE1KCNH2BACE2APP | |
| SCHEMBL8218866 | 0.85 | BACE1 (0.66) | BACE1KCNH2BACE2APP | |
| SCHEMBL8220738 | 0.85 | BACE1 (0.66) | BACE1KCNH2BACE2APP | |
| Hydrochloric Acid SCHEMBL12272746 | 0.84 | BACE1 (0.64) | BACE1KCNH2BACE2APP | |
| Hydrochloric Acid SCHEMBL12273207 | 0.84 | BACE1 (0.64) | BACE1KCNH2BACE2APP | |
| SCHEMBL11307683 | 0.84 | BACE1 (0.47) | BACE1KCNH2BACE2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242943-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | SIENA BIOTECH S.P.A. (IT) | 2016-01-26 | — | — | US | disclosed |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | disclosed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184540-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885KCNH2 3618/4885BACE2 1/4885 |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | BACE1 2/4885KCNH2 3216/4885BACE2 1/4885 |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885KCNH2 3694/4885BACE2 1/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | BACE1 2/4885KCNH2 2857/4885BACE2 1/4885 |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | BACE1 2/4885KCNH2 2857/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.